[AMPH] Amphastar Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 20.43 Change: 0.37 (1.84%)
Ext. hours: Change: 0 (0%)

chart AMPH

Refresh chart

Description: Amphastar Pharmaceuticals, Inc., a generic and specialty pharmaceutical company, engages in the discovery, development, manufacture, and marketing of generic and proprietary pharmaceuticals, delivery systems, and active pharmaceutical ingredients. The company focuses on injectable, inhalation, and other categories of pharmaceutical products. Its products include Enoxaparin Sodium Injection, which is indicated for the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism and the inpatient/outpatient treatment of acute deep vein thrombosis; Amphadase, a protein enzyme that is prepared from a highly purified bovine testicular hyaluronidase; Cortrosyn for Injection, a diagnostic agent that is used in the screening of patients presumed to have adrenocortocal insufficiency; and prefilled disposable emergency syringes for crash cart use. The company?s products also include Lidocaine HCl Jelly, a preservative-free topical local anesthetic agent that is provided in a prefilled syringe; Naloxone HCl

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS0.15 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 16.09% Sales Growth - Q/Q1.81% P/E110.8
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-2.46% ROE-3.49% ROI-3.08%
Current Ratio2.81 Quick Ratio1.63 Long Term Debt/Equity0.27 Debt Ratio0.26
Gross Margin23.49% Operating Margin-10.51% Net Profit Margin-4.4% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities4.45 M Cash From Investing Activities-5.04 M Cash From Operating Activities1.34 M Gross Profit13.28 M
Net Profit-670 K Operating Profit-7.26 M Total Assets396.5 M Total Current Assets202.6 M
Total Current Liabilities72.09 M Total Debt48.42 M Total Liabilities117.22 M Total Revenue56.89 M
Technical Data
High 52 week25.28 Low 52 week17.13 Last close20.64 Last change-2.04%
RSI65.36 Average true range0.71 Beta0.95 Volume248.19 K
Simple moving average 20 days3.79% Simple moving average 50 days2.48% Simple moving average 200 days-1.94%
Performance Data
Performance Week3.88% Performance Month3.15% Performance Quart-7.9% Performance Half-10.1%
Performance Year14.86% Performance Year-to-date3.72% Volatility daily1.98% Volatility weekly4.44%
Volatility monthly9.09% Volatility yearly31.49% Relative Volume233.02% Average Volume182.87 K
New High New Low

News

2019-09-21 07:58:08 | How Much Did Amphastar Pharmaceuticals, Inc.'s NASDAQ:AMPH CEO Pocket Last Year?

2019-09-12 21:15:02 | Amphastar Pharmaceuticals Inc AMPH CEO & Chief Scientific Officer Jack Y. Zhang Sold $6. ...

2019-08-29 06:01:00 | Amphastar Pharmaceuticals to Present at the Wells Fargo 2019 Healthcare Conference

2019-08-22 08:44:31 | Does Amphastar Pharmaceuticals NASDAQ:AMPH Have A Healthy Balance Sheet?

2019-08-08 11:59:39 | Edited Transcript of AMPH earnings conference call or presentation 7-Aug-19 9:00pm GMT

2019-08-07 23:24:11 | Amphastar Pharmaceuticals Inc AMPH Q2 2019 Earnings Call Transcript

2019-08-07 20:55:12 | Amphastar Pharmaceuticals AMPH Q2 Earnings and Revenues Beat Estimates

2019-08-07 16:05:00 | Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2019

2019-08-05 06:00:00 | Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 7, 2019

2019-07-23 13:19:54 | Should You Be Holding Amphastar Pharmaceuticals, Inc. NASDAQ:AMPH?

2019-06-29 18:18:02 | Is Amphastar Pharmaceuticals Inc AMPH A Good Stock To Buy ?

2019-06-24 06:00:00 | Amphastar Pharmaceuticals to Present at the BMO Prescriptions for Success Healthcare Conference

2019-06-19 06:00:00 | Amphastar Pharmaceuticals, Inc. Announces Settlement in Litigation with Momenta and Sandoz

2019-06-14 14:07:25 | Introducing Amphastar Pharmaceuticals NASDAQ:AMPH, A Stock That Climbed 33% In The Last Three Years

2019-06-14 06:00:00 | Amphastar Pharmaceuticals to Present at the Raymond James Life Sciences and MedTech Healthcare Conference

2019-05-31 06:00:00 | Amphastar Pharmaceuticals to Present at the Jefferies 2019 Healthcare Conference

2019-05-28 14:47:43 | 7 Stocks to Buy for June

2019-05-10 18:08:28 | Edited Transcript of AMPH earnings conference call or presentation 9-May-19 9:00pm GMT

2019-05-10 06:00:00 | Amphastar Pharmaceuticals to Present at the Bank of America Merrill Lynch Healthcare Conference 2019

2019-05-10 00:24:08 | Amphastar Pharmaceuticals Inc AMPH Q1 2019 Earnings Call Transcript

2019-05-09 19:05:11 | Amphastar Pharmaceuticals AMPH Q1 Earnings and Revenues Surpass Estimates

2019-05-09 17:58:21 | Amphastar: 1Q Earnings Snapshot

2019-05-09 16:05:00 | Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2019

2019-05-07 10:56:37 | Here’s What Hedge Funds Think About Amphastar Pharmaceuticals Inc AMPH

2019-05-06 06:00:00 | Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 9, 2019

2019-05-01 10:33:02 | Amphastar Pharmaceuticals AMPH to Report Q1 Results: Wall Street Expects Earnings Growth

2019-04-26 09:30:01 | MNK or AMPH: Which Is the Better Value Stock Right Now?

2019-04-25 15:13:50 | Do Insiders Own Shares In Amphastar Pharmaceuticals, Inc. NASDAQ:AMPH?

2019-04-15 09:30:00 | Small Cap Pot Stocks Can Bring Investors High Profits-THC Therapeutics, Inc.

2019-04-10 09:30:01 | MNK vs. AMPH: Which Stock Is the Better Value Option?

2019-03-26 17:32:59 | Amid talk of buyout, Peninsula biotech zeroes in on its blood-thinner antidote

2019-03-25 09:30:01 | MNK vs. AMPH: Which Stock Should Value Investors Buy Now?

2019-03-19 07:40:42 | The Daily Biotech Pulse: FDA Nod For Roche And Amphastar, Milestone Payment Kicks In For Affimed

2019-03-19 06:00:00 | Amphastar Pharmaceuticals Receives FDA Approval for Enoxaparin Sodium Injection 300mg/3mL 100mg/mL Multiple Dose Vial

2019-03-15 07:48:08 | Amphastar Pharmaceuticals Inc AMPH Files 10-K for the Fiscal Year Ended on December 31, 2018

2019-03-13 16:17:11 | This Biotech Sees Markets Worth Billions — But Can It Survive A 'Pause'?

2019-03-13 10:24:20 | Does Market Volatility Impact Amphastar Pharmaceuticals, Inc.’s NASDAQ:AMPH Share Price?

2019-03-13 09:24:10 | Edited Transcript of AMPH earnings conference call or presentation 12-Mar-19 9:00pm GMT

2019-03-13 02:36:44 | Amphastar Pharmaceuticals AMPH Q4 2018 Earnings Conference Call Transcript

2019-03-12 19:10:11 | Amphastar Pharmaceuticals AMPH Beats Q4 Earnings and Revenue Estimates

2019-03-12 18:16:14 | Amphastar: 4Q Earnings Snapshot

2019-03-12 16:05:00 | Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2018

2019-03-12 15:00:00 | Amphastar Pharmaceuticals Inc to Host Earnings Call

2019-03-12 07:31:32 | Amphastar Pharmaceutical Q4 Earnings Preview

2019-03-08 09:30:02 | MNK vs. AMPH: Which Stock Should Value Investors Buy Now?

2019-03-07 16:01:00 | Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on March 12, 2019

2019-02-26 08:15:00 | Market Trends Toward New Normal in Micron Technology, Harris, Sientra, Noble, Amphastar Pharmaceuticals, and CECO Environmental — Emerging Consolidated Expectations, Analyst Ratings

2019-02-13 09:30:02 | MNK vs. AMPH: Which Stock Should Value Investors Buy Now?

2019-01-29 13:38:39 | Who Has Been Selling Amphastar Pharmaceuticals, Inc. NASDAQ:AMPH Shares?

2019-01-28 09:30:02 | MNK vs. AMPH: Which Stock Should Value Investors Buy Now?